Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Illumina nets $390mm in placement of convertible debt

Executive Summary

Illumina (tools for genetic analysis) netted $390.3mm through the placement of $400mm principal amount (including the overallotment) of 0.625% convertible senior notes due 2014 to Goldman Sachs and Deutsche Bank. The conversion price for the notes is $43.66 per share. (Illumina's market average was $35.98 at the time of the placement.)
Deal Industry
  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Nanotechnology, Chips, etc.
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Research, Analytical Equipment & Supplies
    • PCR & Amplification Tools
Deal Status
  • Final
Deal Type
  • Financing
    • Convertible Debt
    • Private Placement

Related Companies

Advertisement
UsernamePublicRestriction

Register